ArticleCancer medicine2025
A 39-Year Nationwide Study of Uveal Melanoma in Taiwan.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Feasibility of Low-Pass Whole Genome Sequencing for Detecting Somatic Copy Number Alterations in Formalin-Fixed Uveal Melanoma Specimens.Translational vision science & technology · 2025Article
- Gastric Melanoma in A 19-Year-Old Patient: A Rare Case and A Review of Diagnostic Pitfalls.European journal of case reports in internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the incidence, treatment strategies, and survival outcomes of adult patients with uveal melanoma (UM) in Taiwan over a 39-year period.
designWe conducted a retrospective, nationwide population-based cohort study retrieving data from the Taiwan Cancer Registry and the National Death Registry of Health and Welfare Data Science Center database. By employing the International Classification of Diseases diagnostic codes, we identified patients who were diagnosed with UM between January 1980 and December 2018. We analyzed treatment information, as well as mortality data, to gain a comprehensive understanding of the incidence, patient characteristics, treatment patterns, and survival outcomes.
resultsA total of 314 patients (156 males and 158 females) were diagnosed with UM. The overall incidence rate was 0.36 (range: 0.30-0.42) per million persons, with a mean age at diagnosis of 52 years. In terms of treatment options, enucleation was performed on 122 patients (38.9%), whereas 108 (34.4%) received radiotherapy (RT). The remaining 84 (26.8%) patients underwent alternative treatments. The 5-year overall survival (OS) rate was 58.3%. Pairwise comparisons showed that the OS rates of patients who underwent RT versus surgery were similar. Two factors were associated with favorable OS outcomes: being under 50 years of age (p < 0.001) and being a female (p = 0.04).
conclusionsOur real-world study encompassing a 39-year timeframe revealed a relatively low incidence of UM within the Taiwanese population. Patients under the age of 50, as well as females, demonstrated more favorable OS outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.